Teleflex (NYSE:TFX) announced today that it released its new Arrow pressure injectable midline portfolio of catheters in North America.

Wayne, Pennsylvania-based Teleflex designed its Arrow portfolio to help alleviate line identification confusion. The company said a lack of identification between midlines and catheters creates the potential for mistaken infusions. Clinicians could infuse medications through midlines that should only be infused through a central venous access device. Complications from this can cause disruption in therapy and potentially lead to line replacement.

Clinicians can now choose between the Arrowg+ard Blue Advance Midline with antimicrobial and antithrombogenic protection or the traditional Arrow Midline. Teleflex offers both in single and double-lumen options. It launched the catheters in the U.S. and Canada.

Teleflex’s portfolio includes clinician-inspired updates. The yellow-colored catheter features and labeling help to reduce line confusion. Meanwhile, the platform features 14 different kit configurations, all with pressure injection capabilities. This aims to mitigate risks and improve efficiency.

Additionally, a new Arrow ergonomic trimmer allows for multiple precise cuts and easy visualization. The portfolio includes  one-piece, full-body fenestrated drape, ultrasound probe cover with gel, and Tegaderm CHG securement dressing.

“The Arrowg+ard Blue Advance midline catheter portfolio provides protection by reducing thrombus accumulation and the primary pathogens responsible for most healthcare-associated infections,” said Lisa Kudlacz, president and GM of Baxter’s vascular access division. “With multiple levels of protection, critical innovations, and a streamlined workflow, it’s the perfect solution to deliver vital medications.”